Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals

Clinical Therapeutics

Volumn 28, Issue 7, 2006, Pages 1054-1062

  Coleman, Craig I ^a,b   McKay, Raymond G ^a   Boden, William E ^a,c   Mather, Jeffrey F ^a   White, C Michael ^a,b  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

acute myocardial infarction; angioplasty; facilitated percutaneous coronary intervention; thrombolytics

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; COMMUNITY HOSPITAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; EMERGENCY SURGERY; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HOSPITAL CHARGE; HUMAN; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONPARAMETRIC TEST; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; SCORING SYSTEM; STANDARD; STROKE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DATA INTERPRETATION, STATISTICAL; DRUG UTILIZATION; FEMALE; HEALTH CARE SURVEYS; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; SEX FACTORS; SLEEP DISORDERS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 33748610796     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.07.007     Document Type: Article

References (21)

1. Weinstock B. Contemporary management of ST elevation myocardial infarction. Sem Thromb Hemost 30 (2004) 673-681
2. [published correction appears in JAMA. 1998;279:1876]. Weaver W., Simes R., Betriu A., et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 278 (1997) 2093-2098
3. Simes R., Topol E., Holmes Jr. D., et al., GUSTO-I Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 91 (1995) 1923-1928
4. Ross A., Coyne K., Moreyra E., et al., GUSTO-I Angiographic Investigators. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 97 (1998) 1549-1556
5. Andersen H., Nielsen T., Rasmussen K., et al., DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349 (2003) 733-742
6. Hirsh J., Guyatt G., Albers G., et al. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-based guidelines. Chest. 126 (2004) 172S-173S
7. Nallamothu B., Bates E., Herrin J., et al., NRMI Investigators. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111 (2005) 761-767
8. (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) [published correction appears in J Am Coll Cardiol. 2005;45:1376]. Antman E., Anbe D., Armstrong P., et al., American College of Cardiology, American Heart Association, Canadian Cardiovascular Society. ACC/AHA guide-lines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Taks Force on Practice Guidelines. J Am Coll Cardiol 44 (2004) 671-719
9. [abstract]. de Lemos J., Gibson C., Antman E., et al. Abciximab improves microvascular function after rescue PCI: A TIMI 14 substudy. Abstract 843-6. J Am Coll Cardiol 35 Suppl A (2000) 40A
10. Topol E., and GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 357 (2001) 1905-1914
11. Giugliano R., Roe M., Harrington R., et al., INTEGRITI Investigators. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the integerilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 41 (2003) 1251-1260
12. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
13. D'Agostino Jr. R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 17 (1998) 2265-2281
14. American College of Cardiology National Cardiovascular Data Registry Cardiac Catheterization Module 3.04 Data Definitions (2004), American College of Cardiology. http://www.accncdr.com/WebNCDR/NCDRDocuments/datadictdefsonlyv30.pdf
15. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Lancet 354 (1999) 716-722
16. Eisenberg J. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 262 (1989) 2879-2886
17. Luce B., Manning W., Siegel J., and Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Gold M., Siegel J., Russell L., and Weinstein M. (Eds). Cost-effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY 176-213
18. Available at. US Bureau of Labor Statistics. Accessed February 24, 2005. Consumer Price Index Detailed Report (March 2004), Department of Labor, Washington, DC. http://www.bls.gov/cpi/cpid0403.pdf
19. Brener S., Barr L., Burchenal J., et al., ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98 (1998) 734-741
20. Hunink M., Bult J., de Vries J., and Weinstein M. Uncertainty in decision models analyzing cost-effectiveness: The joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 18 (1998) 337-346
21. Available at. Wood S. Facilitated PCI using abciximab plus reteplase awaits FINESSE trial, BRAVE investigators say. Accessed April 28, 2005 (February 24, 2004). http://www.theheart.org/article/224025.do